Pharma Spent More Than $48B in China in H1, Eclipsing Total 2024 Haul
If the trend holds, IQVIA expects 2025 deal volume between Chinese and multinational companies to easily eclipse the 100 agreements signed in 2024.Read more:
biospace.comBiotechnology